Skip to content | Change text size
 

Professor William N Charman

Dean
Director, Monash Institute of Pharmaceutical Sciences

BPharm Victorian College of Pharmacy
PhD University of Kansas (USA)

Phone: +61 3 9903 9502
Fax: +61 3 9903 9581
Email: bill.charman@pharm.monash.edu.au

Director, Monash Institute of Pharmaceutical Sciences

Research interests

  • Oral drug delivery, bioavailability enhancement and lymphatic drug transport
  • Lipid-based formulation design and assessment
  • Drug discovery and lead optimisation in infectious disease (particularly neglected diseases including malaria) and cancer
  • Pre-clinical development of new drug candidates

Representative publications

  1. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, Dong Y, Vennerstrom JL, et.al. Relationship between antimalarial activity and heme alkylation for spiro- and  dispiro-1,2,4-trioxolane  antimalarials. Antimicrob Agents Chemother. 2008; 52:1291-1296.
  2. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, McCullough KJ, Dong Y, et.al. Iron mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials. J Pharm Sci. 2007; 96:2945-2956.
  3. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimising the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery. 2007; 6:231-248.
  4. Trevaskis NL, Porter CJH, Charman WN. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos. 2006; 34:729-733.
  5. Trevaskis NL, Porter CJH, Charman WN. The lymph lipid precursor pool is a key determinate of intestinal lymphatic drug transport. J Pharmacol Exp Ther. 2006; 316:881-891.
  6. Perry CS, Charman SA, Prankerd RJ, Chiu FCK, Dong Y, Charman WN, et.al. Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials. J Pharm Sci. 2006; 95:737-747.
  7. Charman SA, Perry CS, Chiu FCK, McIntosh KA, Charman WN. Alteration of the pharmacokinetics of a new chemical entity in the presence of a substituted cyclodextrin. J Pharm Sci. 2006; 95:256-267.
  8. Trevaskis NL, Porter CJH, Charman WN. Bile increases intestinal lymphatic drug transport in the rat. Pharm Res. 2005; 22:1863-1870.
  9. Creek DJ, Chiu FCK, Prankerd RJ, Charman SA, Charman WN. Kinetics of iron-mediated artemisinin degradation: Effect of solvent composition and iron salt. J Pharm Sci. 2005; 94:1820-1829.
  10. Velkov T, Chung S, Wielens J, Sakellaris H, Charman WN, Porter CJH, et.al. The interaction of lipophilic drugs with intestinal fatty acid binding protein. J Biol Chem. 2005; 280:17769-17776.
  11. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, FCK Chiu, Charman WN, et.al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004; 430:900-904.
  12. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol administered as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004; 21:1405-1412.
  13. Kossena GA, Charman WN, Boyd BJ, Dunstan DE, Porter CJH. Probing drug solubilisation patterns in the gastrointestinal tract after administration of lipid based delivery systems: A phase diagram approach. J Pharm Sci. 2004; 93:332-348.
  14. Shackleford DM, Fassen WA, Houwing N, Lass H, Edwards GA, Charman WN, et.al. The contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph-duct cannulated dogs. J Pharmacol Exp Ther. 2003; 306:925-933.
  15. Johnson BM, Chen W, Borchardt RT, Charman WN, Porter CJH. A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther. 2003; 305:151-158.
  16. Khoo SM, Prankerd RJ, Edwards GA, Porter CJH, Charman WN. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after post-prandial administration to dogs. J Pharm Sci. 2002; 91:647-659.
  17. Khoo SM, Edwards GA, Porter CJH, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001; 90:1599-1607.
  18. Charman WN. Lipids, lipophilic drugs, and oral drug delivery – some emerging concepts. J Pharm Sci. 200; 89:967-978.
  19. Krise JP, Charman WN, Charman SA, Stella VJ. A novel prodrug approach for tertiary amines III: In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. J Pharm Sci. 1999; 88:928-932.
  20. Charman WN, Porter CJH, Mithani S, Dressman JB.   Physicochemical and physiological mechanisms for the effects of food on drug absorption: The effect of lipids and pH. J Pharm Sci. 1997; 86:269-282.

External appointments

  • Chair, Seeding Drug Discovery Committee, Wellcome Trust, London, UK
  • Deputy Chair, Expert Scientific Advisory Committee, Medicines for Malaria Venture, Geneva, Switzerland
  
Professor William N Charman

See Professor Charman's biography